Inceptor Bio is building a diversified cell therapy portfolio with differentiation that matters across multiple cell types including T cells, Macrophages, and Natural Killers.
Cell-based immunotherapy represents a new frontier in the treatment of cancer. While there has been tremendous innovation in cell-based therapies, cancers such as solid tumors remain very difficult to treat. With our focus on multiple effector cells, we believe that we are well positioned to make an impact across difficult-to-treat cancers.
Inceptor Bio’s CAR-T platform is based on a novel co-stimulatory domain platform, M-STIM, that generates expansion kinetics that are differentiated from the CAR-T therapies currently on the market.
Inceptor Bio’s CAR-M platform enhances the unique capabilities of macrophages to target and engulf cancer cells.
Inceptor Bio is focused on multiple specific cell & gene therapy technology platforms, including those covered below:
CAR-T cells are engineered to identify and kill cancer cells. There are multiple CAR-T therapies that have earned FDA approval.
CAR-Macrophages have the ability to access solid tumors, survive in their hostile environment, selectively destroy cancer cells, and activate an adaptive immune response by presenting engulfed tumor material.
CAR-Natural Killer cells are engineered to identify and attack cancer. Safety (avoiding GvHd) and accessibility (allogeneic) are two strong advantages.
Gamma Delta T cells (γδ T Cells) are cells that express a unique T cell receptor, composed of one γ-chain and one δ-chain.
A type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living cell, either in vivo or ex vivo.